JPH0253731A - 抗癌活性物質 - Google Patents
抗癌活性物質Info
- Publication number
- JPH0253731A JPH0253731A JP63203016A JP20301688A JPH0253731A JP H0253731 A JPH0253731 A JP H0253731A JP 63203016 A JP63203016 A JP 63203016A JP 20301688 A JP20301688 A JP 20301688A JP H0253731 A JPH0253731 A JP H0253731A
- Authority
- JP
- Japan
- Prior art keywords
- precipitate
- organic solvent
- active substance
- carcinostatic
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013543 active substance Substances 0.000 title claims abstract description 13
- 230000003327 cancerostatic effect Effects 0.000 title abstract 3
- 239000002244 precipitate Substances 0.000 claims abstract description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000003960 organic solvent Substances 0.000 claims abstract description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 230000001093 anti-cancer Effects 0.000 claims description 24
- 239000000284 extract Substances 0.000 claims description 10
- 241001261506 Undaria pinnatifida Species 0.000 claims description 9
- 241001474374 Blennius Species 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 8
- 239000007788 liquid Substances 0.000 abstract description 7
- 238000000926 separation method Methods 0.000 abstract description 6
- 239000012153 distilled water Substances 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 3
- 241000219198 Brassica Species 0.000 abstract 2
- 235000003351 Brassica cretica Nutrition 0.000 abstract 2
- 235000003343 Brassica rupestris Nutrition 0.000 abstract 2
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 abstract 2
- 235000010460 mustard Nutrition 0.000 abstract 2
- 241000195493 Cryptophyta Species 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 description 19
- 229920001282 polysaccharide Polymers 0.000 description 19
- 239000005017 polysaccharide Substances 0.000 description 19
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 201000005202 lung cancer Diseases 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 5
- 229930105110 Cyclosporin A Natural products 0.000 description 5
- 108010036949 Cyclosporine Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 229960001265 ciclosporin Drugs 0.000 description 5
- 229930182912 cyclosporin Natural products 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- BIXYYZIIJIXVFW-UUOKFMHZSA-N (2R,3R,4S,5R)-2-(6-amino-2-chloro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O BIXYYZIIJIXVFW-UUOKFMHZSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 239000012212 insulator Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- MYKOKMFESWKQRX-UHFFFAOYSA-N 10h-anthracen-9-one;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 MYKOKMFESWKQRX-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- YLDCUKJMEKGGFI-QCSRICIXSA-N 4-acetamidobenzoic acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;1-(dimethylamino)propan-2-ol Chemical compound CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2N=C1 YLDCUKJMEKGGFI-QCSRICIXSA-N 0.000 description 1
- FNEHAOQZWPHONV-UHFFFAOYSA-N 9h-carbazole;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C3=CC=CC=C3NC2=C1 FNEHAOQZWPHONV-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 238000011765 DBA/2 mouse Methods 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003409 anti-rejection Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960000834 vinyl ether Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63203016A JPH0253731A (ja) | 1988-08-15 | 1988-08-15 | 抗癌活性物質 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63203016A JPH0253731A (ja) | 1988-08-15 | 1988-08-15 | 抗癌活性物質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0253731A true JPH0253731A (ja) | 1990-02-22 |
| JPH0565491B2 JPH0565491B2 (enrdf_load_stackoverflow) | 1993-09-17 |
Family
ID=16466949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63203016A Granted JPH0253731A (ja) | 1988-08-15 | 1988-08-15 | 抗癌活性物質 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0253731A (enrdf_load_stackoverflow) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007100151A1 (ja) * | 2006-03-03 | 2007-09-07 | Mawatari, Shouji | 免疫賦活剤 |
| JP2016204273A (ja) * | 2015-04-16 | 2016-12-08 | 理研ビタミン株式会社 | サーチュイン遺伝子活性化剤 |
-
1988
- 1988-08-15 JP JP63203016A patent/JPH0253731A/ja active Granted
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007100151A1 (ja) * | 2006-03-03 | 2007-09-07 | Mawatari, Shouji | 免疫賦活剤 |
| JP2016204273A (ja) * | 2015-04-16 | 2016-12-08 | 理研ビタミン株式会社 | サーチュイン遺伝子活性化剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0565491B2 (enrdf_load_stackoverflow) | 1993-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020507619A (ja) | マンヌロン二酸の組成物 | |
| US20030119780A1 (en) | Therapeutical treatments | |
| JPS6152125B2 (enrdf_load_stackoverflow) | ||
| JPH01157995A (ja) | 鎮痛−抗炎症活性を有するガングリオシドの内部エステル | |
| EP0722719A1 (de) | Verfahren zur Herstellung von Flavano-Lignan-Zubereitungen | |
| WO2008145064A1 (fr) | Procédé d'obtention d'un extrait contenant du séquoyitol à partir d'une espèce du genre trifolium, de soja et de ginkgo biloba, et utilisation de celui-ci | |
| JPH0539305A (ja) | アストラガルス・メンブラナセウスから抽出した免疫 変調性多糖類及びこれらを含有する薬剤組成物 | |
| TW201424746A (zh) | 用以治療腸激躁症之山薑屬植物萃取物 | |
| WO1997004791A1 (en) | Antiviral agent and process for preparing the same | |
| JP2013241367A (ja) | 関節リウマチ抑制剤 | |
| JPH0253731A (ja) | 抗癌活性物質 | |
| CN110693026A (zh) | 一种用于改善记忆力的水果成分组合物及其应用 | |
| US3151108A (en) | Kryptoescin and process of making same | |
| CN101547701B (zh) | 增强salicornia brachiata提取物的抗结核活性 | |
| US5710179A (en) | Antitumor agent | |
| JP4424921B2 (ja) | 抗腫瘍剤 | |
| JPH0267301A (ja) | 多糖類，その単離法および該多糖類を含む薬剤組成物 | |
| WO1995006068A1 (fr) | Nouveau polyoside et agent de radioprotection contenant ce nouveau polyoside comme principe actif | |
| WO2007113646A2 (en) | A pharmaceutical composition useful as an immunomodulating agent and a process for the preparation thereof | |
| KR100229288B1 (ko) | 항종양 활성을 갖는 새로운 수용성 다당체 및 그의 제조방법 | |
| JPS63295512A (ja) | 制ガン剤 | |
| JP3968179B2 (ja) | 糖尿病性末梢神経傷害治療剤 | |
| US20100015243A1 (en) | Method for preparing materials having antithrombotic activity from muskrat musk and materials obtained from the method | |
| KR100338521B1 (ko) | 대식세포 활성화능을 갖는 식용식물 추출물 | |
| JPS5849317A (ja) | 抗悪性新生物剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |